These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25083819)

  • 1. Percentage of urinary albumin excretion and serum-free light-chain reduction are important determinants of renal response in myeloma patients with moderate to severe renal impairment.
    Sugihara H; Chihara D; Seike K; Fukumoto K; Fujisawaa M; Suehara Y; Nishida Y; Takeuchi M; Matsue K
    Blood Cancer J; 2014 Aug; 4(8):e235. PubMed ID: 25083819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between serum erythropoietin levels and renal reversibility in patients with renal impairment from multiple myeloma.
    Kobayashi H; Terao T; Tsushima T; Abe Y; Miura D; Narita K; Kitadate A; Takeuchi M; Matsue K
    Cancer Med; 2020 Jun; 9(12):4460-4466. PubMed ID: 32311841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases.
    Leung N; Gertz M; Kyle RA; Fervenza FC; Irazabal MV; Eirin A; Kumar S; Cha SS; Rajkumar SV; Lacy MQ; Zeldenrust SR; Buadi FK; Hayman SR; Nasr SH; Sethi S; Ramirez-Alvarado M; Witzig TE; Herrmann SM; Dispenzieri A
    Clin J Am Soc Nephrol; 2012 Dec; 7(12):1964-8. PubMed ID: 23024162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR.
    Hansen CT; Pedersen PT; Nielsen LC; Abildgaard N
    Eur J Haematol; 2014 Nov; 93(5):407-13. PubMed ID: 24809596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma.
    Yadav P; Cockwell P; Cook M; Pinney J; Giles H; Aung YS; Cairns D; Owen RG; Davies FE; Jackson GH; Child JA; Morgan GJ; Drayson MT
    BMC Nephrol; 2018 Jul; 19(1):178. PubMed ID: 30012107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.
    Hutchison CA; Cockwell P; Stringer S; Bradwell A; Cook M; Gertz MA; Dispenzieri A; Winters JL; Kumar S; Rajkumar SV; Kyle RA; Leung N
    J Am Soc Nephrol; 2011 Jun; 22(6):1129-36. PubMed ID: 21511832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV).
    Holzhey T; Pönisch W; Wang SY; Holzvogt M; Holzvogt B; Andrea M; Zehrfeld T; Hammerschmidt D; Hoffmann FA; Becker C; Schwarzer A; Schwarz M; Schönfelder-Fricke U; Edelmann T; Braunert L; Franke GN; Jentzsch M; Schwind S; Bill M; Grimm J; Remane Y; Platzbecker U; Scholz M
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2349-2359. PubMed ID: 33433659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expert consensus for the diagnosis and treatment of patients with renal impairment of multiple myeloma].
    Renal Impairment of Multiple Myeloma Collaborative Study Group
    Zhonghua Nei Ke Za Zhi; 2017 Nov; 56(11):871-875. PubMed ID: 29136724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients.
    Chen X; Luo X; Zu Y; Issa HA; Li L; Ye H; Yang T; Hu J; Wei L
    J Clin Lab Anal; 2020 Sep; 34(9):e23416. PubMed ID: 32710448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
    van Rhee F; Bolejack V; Hollmig K; Pineda-Roman M; Anaissie E; Epstein J; Shaughnessy JD; Zangari M; Tricot G; Mohiuddin A; Alsayed Y; Woods G; Crowley J; Barlogie B
    Blood; 2007 Aug; 110(3):827-32. PubMed ID: 17416735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.
    Ludwig H; Adam Z; Hajek R; Greil R; Tóthová E; Keil F; Autzinger EM; Thaler J; Gisslinger H; Lang A; Egyed M; Womastek I; Zojer N
    J Clin Oncol; 2010 Oct; 28(30):4635-41. PubMed ID: 20823423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activin A: a novel urinary biomarker of renal impairment in multiple myeloma.
    Iriuchishima H; Maeshima A; Takahashi S; Ishizaki T; Yokohama A; Tsukamoto N; Saitoh T; Murakami H; Handa H
    Biosci Rep; 2019 May; 39(5):. PubMed ID: 31072919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.
    Morabito F; Gentile M; Mazzone C; Rossi D; Di Raimondo F; Bringhen S; Ria R; Offidani M; Patriarca F; Nozzoli C; Petrucci MT; Benevolo G; Vincelli I; Guglielmelli T; Grasso M; Marasca R; Baldini L; Montefusco V; Musto P; Cascavilla N; Majolino I; Musolino C; Cavo M; Boccadoro M; Palumbo A
    Blood; 2011 Nov; 118(22):5759-66. PubMed ID: 21951682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Light chain deposition disease without glomerular proteinuria: a diagnostic challenge for the nephrologist.
    Sicard A; Karras A; Goujon JM; Sirac C; Bender S; Labatut D; Callard P; Sarkozy C; Essig M; Vanhille P; Provot F; Nony A; Nochy D; Ronco P; Bridoux F; Touchard G
    Nephrol Dial Transplant; 2014 Oct; 29(10):1894-902. PubMed ID: 24619059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
    Zannetti BA; Zamagni E; Santostefano M; De Sanctis LB; Tacchetti P; Mancini E; Pantani L; Brioli A; Rizzo R; Mancuso K; Rocchi S; Pezzi A; Borsi E; Terragna C; Marzocchi G; Santoro A; Cavo M
    Am J Hematol; 2015 Jul; 90(7):647-52. PubMed ID: 25858483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients.
    Ecotière L; Thierry A; Debiais-Delpech C; Chevret S; Javaugue V; Desport E; Belmouaz S; Quellard N; Kaaki S; Goujon JM; Fermand JP; Touchard G; Bridoux F
    Nephrol Dial Transplant; 2016 Jan; 31(1):64-72. PubMed ID: 26289418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients.
    Kleber M; Ihorst G; Deschler B; Jakob C; Liebisch P; Koch B; Sezer O; Engelhardt M
    Eur J Haematol; 2009 Dec; 83(6):519-27. PubMed ID: 19614956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry.
    Ho PJ; Moore EM; McQuilten ZK; Wellard C; Bergin K; Augustson B; Blacklock H; Harrison SJ; Horvath N; King T; Mollee P; Quach H; Reid C; Rosengarten B; Walker P; Wood EM; Spencer A
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e415-e424. PubMed ID: 31208889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.
    Dimopoulos MA; Roussou M; Gavriatopoulou M; Psimenou E; Eleutherakis-Papaiakovou E; Migkou M; Matsouka C; Mparmparousi D; Gika D; Kafantari E; Ziogas D; Fotiou D; Panagiotidis I; Terpos E; Kastritis E
    Am J Hematol; 2016 May; 91(5):499-502. PubMed ID: 26890495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
    Morabito F; Gentile M; Ciolli S; Petrucci MT; Galimberti S; Mele G; Casulli AF; Mannina D; Piro E; Pinotti G; Palmieri S; Catalano L; Callea V; Offidani M; Musto P; Bringhen S; Baldini L; Tosi P; Di Raimondo F; Boccadoro M; Palumbo A; Cavo M
    Eur J Haematol; 2010 Mar; 84(3):223-8. PubMed ID: 19930441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.